Arcutis' ZORYVE Crème SNDA Accepted By FDA For Infants With Atopic Dermatitis

Arcutis Biotherapeutics announced the FDA accepted its supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%. FDA acceptance is a procedural milestone that supports continued review, keeping the regulatory pathway active. The news is modestly positive but not yet indicative of final approval, so near-term market impact is likely limited.

Analysis

Arcutis Biotherapeutics announced the FDA accepted its supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%. FDA acceptance is a procedural milestone that supports continued review, keeping the regulatory pathway active. The news is modestly positive but not yet indicative of final approval, so near-term market impact is likely limited.